PRESS RELEASE published on 08/14/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Publishes 2025 Half-Year Report Relief Therapeutics published its 2025 half-year report, highlighting progress in pipeline candidates for rare diseases and financial status. Corporate update includes advances in wound care and liquid formulation for phenylketonuria Financial Status Relief Therapeutics Rare Diseases 2025 Half-Year Report Pipeline Candidates
BRIEF published on 08/11/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Advances 2025 Half-Year Report Publication Biopharmaceutical Company Relief Therapeutics Innovative Treatments Geneva Half-Year Report 2025
BRIEF published on 08/11/2025 at 07:05, 1 year 2 months ago Publication du rapport semestriel 2025 de Relief Therapeutics THÉRAPEUTIQUE DE SECOURS Traitements Innovants Genève Société Biopharmaceutique Rapport Semestriel 2025
PRESS RELEASE published on 08/11/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Advances Publication of 2025 Half-Year Report Relief Therapeutics advances publication of its 2025 half-year report from August 27 to August 14, 2025, indicating completion ahead of schedule. Company to provide shareholder update and financial statements Biopharmaceutical Relief Therapeutics Publication Innovative Treatment Options 2025 Half-Year Report
BRIEF published on 07/29/2025 at 07:05, 1 year 3 months ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
BRIEF published on 07/29/2025 at 07:05, 1 year 3 months ago Relief Therapeutics et NeuroX fusionnent, développant ainsi leur technologie de santé basée sur l'IA SIX Swiss Exchange Fusions Et Acquisitions Maladies Neurologiques MindMaze Technologie De La Santé Basée Sur L'IA
PRESS RELEASE published on 07/29/2025 at 07:00, 1 year 3 months ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 1 year 4 months ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
BRIEF published on 06/20/2025 at 07:05, 1 year 4 months ago Relief Therapeutics fait face à un revers de la FDA concernant la désignation QIDP du RLF-TD011 RLF-TD011 Médicament Orphelin Réponse De La FDA Epidermolyse Bulleuse Désignation QIDP
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year 4 months ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
Published on 11/09/2026 at 23:10, 8 hours 35 minutes ago Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 8 hours 45 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 9 hours 13 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 9 hours 30 minutes ago Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley
Published on 11/10/2026 at 07:38, 6 minutes ago Elmos Semiconductor SE continues profitable growth and strong cash generation in the third quarter of 2026
Published on 11/10/2026 at 07:30, 14 minutes ago Henkel posts very strong sales growth in the third quarter
Published on 11/10/2026 at 07:30, 15 minutes ago R. STAHL sales and profitability on track after nine months – Stabilization continues as planned – Forecast for 2026 confirmed
Published on 11/10/2026 at 07:30, 15 minutes ago Infineon closes FY 2026 with record quarter; expects revenue growth of more than 20 percent and a 5-percentage-point increase in profitability for FY 2027
Published on 11/10/2026 at 07:30, 15 minutes ago AUTO1 Group appoints Jörg Pietzner as Chief Financial Officer
Published on 11/10/2026 at 07:00, 45 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 45 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 13 hours 15 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 13 hours 15 minutes ago Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
